ACRO Biomedical Co., Ltd. (TPEX:6748)
Taiwan · Delayed Price · Currency is TWD 173.50
-10.50 (-5.71%)
Sep 8, 2026, 12:49 PM CST
ACRO Biomedical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 52.76 | 38.26 | 44.23 | 51.06 | 27.63 | 21.83 | |
Revenue Growth | 44.54% | -13.51% | -13.38% | 84.79% | 26.59% | 21.04% |
Cost of Revenue | 18.91 | 19.73 | 18.04 | 11.95 | 14.21 | 7.29 |
Gross Profit | 33.85 | 18.53 | 26.19 | 39.12 | 13.43 | 14.54 |
Selling, General & Admin | 93.52 | 80.58 | 66.97 | 55.59 | 48.36 | 42.05 |
Research & Development | 34.06 | 30.83 | 25.72 | 28.64 | 27.85 | 26.04 |
Operating Expenses | 127.92 | 110.74 | 90.84 | 87.79 | 76.2 | 68.1 |
Operating Income | -94.07 | -92.22 | -64.65 | -48.67 | -62.78 | -53.56 |
Interest Expense | -0.3 | -0.22 | -0.29 | -0.26 | -0.1 | -0.09 |
Interest & Investment Income | 8.16 | 6.45 | 4.35 | 2.33 | 0.8 | 0.32 |
Currency Exchange Gain (Loss) | -0.68 | -0.15 | -0.19 | -0.24 | -0.65 | 0.08 |
Other Non Operating Income (Expenses) | 1.86 | 2.11 | 0.19 | 2.65 | 1.35 | 0.66 |
EBT Excluding Unusual Items | -85.03 | -84.04 | -60.59 | -44.19 | -61.38 | -52.59 |
Gain (Loss) on Sale of Investments | 6.24 | 1.4 | -1.33 | 2.77 | 0.5 | 1.81 |
Gain (Loss) on Sale of Assets | - | -0.02 | -0.15 | - | - | - |
Pretax Income | -78.79 | -82.66 | -62.07 | -41.42 | -60.88 | -50.78 |
Income Tax Expense | - | - | 0.02 | - | - | - |
Net Income | -78.79 | -82.66 | -62.09 | -41.42 | -60.88 | -50.78 |
Net Income to Common | -78.79 | -82.66 | -62.09 | -41.42 | -60.88 | -50.78 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 66 | 61 | 61 | 53 | 47 | 35 |
Shares Outstanding (Diluted) | 66 | 61 | 61 | 53 | 47 | 35 |
Shares Change | 8.21% | 0.04% | 16.17% | 11.22% | 33.71% | 17.22% |
EPS (Basic) | -1.19 | -1.35 | -1.01 | -0.79 | -1.29 | -1.43 |
EPS (Diluted) | -1.19 | -1.35 | -1.01 | -0.79 | -1.29 | -1.43 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -81.55 | -61.83 | -73.93 | -69.27 | -47.89 | -48.2 |
Free Cash Flow Per Share | -1.23 | -1.01 | -1.21 | -1.31 | -1.01 | -1.36 |
Gross Margin | 64.17% | 48.43% | 59.21% | 76.60% | 48.59% | 66.62% |
Operating Margin | -178.30% | -241.06% | -146.17% | -95.31% | -227.17% | -245.35% |
Profit Margin | -149.34% | -216.06% | -140.37% | -81.11% | -220.33% | -232.61% |
Free Cash Flow Margin | -154.57% | -161.62% | -167.13% | -135.66% | -173.30% | -220.80% |
EBITDA | -84.09 | -81.75 | -58.18 | -43.75 | -58 | -47.52 |
EBITDA Margin | -159.39% | -213.70% | -131.54% | -85.69% | -209.91% | -217.68% |
D&A For EBITDA | 9.97 | 10.46 | 6.47 | 4.92 | 4.77 | 6.04 |
EBIT | -94.07 | -92.22 | -64.65 | -48.67 | -62.78 | -53.56 |
EBIT Margin | -178.30% | -241.06% | -146.17% | -95.31% | -227.17% | -245.35% |